Patheon warns 400 jobs at risk as Swindon site trimmed

By Nick Taylor

- Last updated on GMT

Patheon warns 400 jobs at risk as Swindon site trimmed
Patheon may lay off 400 staff at its Swindon, UK site as it moves forward with the restructuring of its facilities.

News of the potential layoffs comes as Patheon makes plans to wind down commercial production at the Swindon, UK plant. Patheon will stop non-cephalosporin commercial manufacture at Swindon, if possible transferring work to other sites, and direct some development business to its other plants.

As Patheon cuts back operations at Swindon over the next two to three years 400 jobs are at risk. A first wave of layoffs is already underway with Patheon detailing plans to cut 91 employees from its global development and commercial production units this week.

When Patheon outlined the plan in September it hoped to sell the Swindon site as a going concern, telling investors early talks with interested parties were underway. However, a filing with the US Securities and Exchange Commission shows Patheon is now readying to wind down operations.

The exception is development services. When planning the sale Patheon said it expected to keep its pharmaceutical development assets at Swindon. Now, as other areas wind down, Swindon will still add development business but direct projects that need commercialisation activities to other sites.

As a result of the restructuring at Swindon Patheon expects to incur an impairment charge of up to $60m (€46m) when it reports its second quarter results. Patheon has allocated a further $5.4m for employee termination benefits in the quarter.

Global changes

Cuts at Swindon are just one part of wide-reaching changes to the footprint of Patheon. The Canada-based CMO (contract manufacturing organisation) is restructuring operations in its home territory and closing a plant in Caguas, Puerto Rico.

In September Jim Mullen, CEO of Patheon, said the changes were needed to “aggressively improve the performance​” of the core business. Mullen admitted financial performance at Patheon has been “uneven at best​”. Since outlining the plan shares in Patheon have risen by more than 20 per cent.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers